标题
Novel therapeutic approaches for haemophilia
作者
关键词
-
出版物
HAEMOPHILIA
Volume 21, Issue 2, Pages 152-161
出版商
Wiley
发表日期
2014-12-19
DOI
10.1111/hae.12615
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Anti-factor IXa/X bispecific antibody ACE910 prevents joint bleeds in a long-term primate model of acquired hemophilia A
- (2014) A. Muto et al. BLOOD
- Phase I study of BAY 94-9027, a PEGylated B-domain-deleted recombinant factor VIII with an extended half-life, in subjects with hemophilia A
- (2014) T. E. Coyle et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics
- (2013) A. Shirahata et al. HAEMOPHILIA
- von Willebrand factor contributes to longer half-life of PEGylated factor VIIIin vivo
- (2013) L. Tang et al. HAEMOPHILIA
- Small Peptides Blocking Inhibition of Factor Xa and Tissue Factor-Factor VIIa by Tissue Factor Pathway Inhibitor (TFPI)
- (2013) Michael Dockal et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Aptamer BAX 499 mediates inhibition of tissue factor pathway inhibitor via interaction with multiple domains of the protein
- (2013) E. K. Waters et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Pharmacological characteristics of a novel, recombinant fusion protein linking coagulation factor VIIa with albumin (rVIIa-FP)
- (2013) S. Zollner et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Improved hemostasis in hemophilia mice by means of an engineered factor Va mutant
- (2013) A. von Drygalski et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- FXIII: mechanisms of action in the treatment of hemophilia A
- (2013) C. J. Rea et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Anti-factor IXa/X bispecific antibody (ACE910): hemostatic potency against ongoing bleeds in a hemophilia A model and the possibility of routine supplementation
- (2013) A. Muto et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Hemostatic effect of a monoclonal antibody mAb 2021 blocking the interaction between FXa and TFPI in a rabbit hemophilia model
- (2012) I. Hilden et al. BLOOD
- A Fully Human, Allosteric Monoclonal Antibody That Activates the Insulin Receptor and Improves Glycemic Control
- (2012) Vinay Bhaskar et al. DIABETES
- Increased prevalence of inhibitors in Hispanic patients with severe haemophilia A enrolled in the Universal Data Collection database
- (2012) S. L. CARPENTER et al. HAEMOPHILIA
- Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors-phase I trial: 2nd report
- (2012) A. Shirahata et al. HAEMOPHILIA
- A bispecific antibody to factors IXa and X restores factor VIII hemostatic activity in a hemophilia A model
- (2012) Takehisa Kitazawa et al. NATURE MEDICINE
- Absence of hematopoietic tissue factor pathway inhibitor mitigates bleeding in mice with hemophilia
- (2012) S. A. Maroney et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Effect of BAX499 aptamer on tissue factor pathway inhibitor function and thrombin generation in models of hemophilia
- (2012) Matthew Gissel et al. THROMBOSIS RESEARCH
- Bioengineered factor Xa as a potential new strategy for hemophilia therapy
- (2012) Rodney M Camire Expert Review of Hematology
- PEGylation of a Factor VIII–Phosphatidylinositol Complex: Pharmacokinetics and Immunogenicity in Hemophilia A Mice
- (2011) Aaron Peng et al. AAPS Journal
- Protective cross talk between activated protein C and TNF signaling in vascular endothelial cells: implication of EPCR, noncanonical NF-κB, and ERK1/2 MAP kinases
- (2011) Christophe Guitton et al. AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
- Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice
- (2011) P. Milanov et al. BLOOD
- Aptamer ARC19499 mediates a procoagulant hemostatic effect by inhibiting tissue factor pathway inhibitor
- (2011) E. K. Waters et al. BLOOD
- Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors - Phase I trial
- (2011) A. SHIRAHATA et al. HAEMOPHILIA
- Activated protein C inhibitor for correction of thrombin generation in hemophilia A blood and plasma1
- (2011) K. E. BRUMMEL-ZIEDINS et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- A zymogen-like factor Xa variant corrects the coagulation defect in hemophilia
- (2011) Lacramioara Ivanciu et al. NATURE BIOTECHNOLOGY
- Protein C anticoagulant system—anti-inflammatory effects
- (2011) Charles T. Esmon Seminars in Immunopathology
- Zymogen-like factor Xa variants restore thrombin generation and effectively bypass the intrinsic pathway in vitro
- (2010) M. W. Bunce et al. BLOOD
- Read-Through Strategies for Suppression of Nonsense Mutations in Duchenne/ Becker Muscular Dystrophy: Aminoglycosides and Ataluren (PTC124)
- (2010) Richard S. Finkel JOURNAL OF CHILD NEUROLOGY
- Factor XIII combined with recombinant factor VIIa: a new means of treating severe hemophilia A
- (2010) C. J. REA et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- An Exosite-Specific ssDNA Aptamer Inhibits the Anticoagulant Functions of Activated Protein C and Enhances Inhibition by Protein C Inhibitor
- (2009) Jens Müller et al. CHEMISTRY & BIOLOGY
- Reduced Clinical Severity in a Mutationally Well-Characterized Cohort of Severe Hemophilia With Associated Thrombophilia
- (2008) Shrimati Shetty et al. AMERICAN JOURNAL OF CLINICAL PATHOLOGY
- Tissue Factor and Factor VIIa as Therapeutic Targets in Disorders of Hemostasis
- (2007) Ulla Hedner et al. Annual Review of Medicine
- Efficacy and safety of a new-class hemostatic drug candidate, AV513, in dogs with hemophilia A
- (2007) S. Prasad et al. BLOOD
- Interdomain engineered disulfide bond permitting elucidation of mechanisms of inactivation of coagulation factor Va by activated protein C
- (2002) Andrew J. Gale et al. PROTEIN SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now